

## NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

### Bladder Cancer

#### Twelfth Guideline Development Group (GDG) meeting

7-8 May 2014

Board Room, NCC-C, Cardiff

#### GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Julia Verne (JV) - Chair	Helen Chilcott (HC)
Pauline Bagnall (PB)	Robert Huddart (RH)
Ben Taylor (BT)	Rob Jones (RJ) (Day 2 only)
Ashish Chandra (ACha) (Day 2 only)	Hugh Mostafid (HM)
Antony Miller (AM)	William Turner (WT)
Jonathan Osborn (JO)	Phil Kelly (PK)
Ananya Choudhury (ACh)	
NCC-C staff	
Angela Bennett (AB)	Matthew Prettyjohns (MP)
Nathan Bromham (NB)	Andrew Champion (AC) (Day 2 only)
Jennifer Hilgart (JH)	John Graham (JG) (Day 1 only)
NICE staff & Affiliated staff	
Judy McBride (JMB)	Luke Hounsome (LH) (Day 1 only)
Raj Jessal (RJ)	
Expert Advisors	
Aoife Gleeson (AG)	
Apologies	
Elise Hasler (EH)	Katie Perryman-Ford (KPF)
Rob Jones (RJ) (Day 1)	Ashish Chandra (ACha) (Day 1)
Luke Hounsome (LH) (Day 2)	
Did not attend	
James Catto (JC)	

#### REPORTS OF DISCUSSION OF THE MEETING

##### 1. Introductions

JV welcomed everyone to the 12th meeting of the bladder cancer GDG, in particular RJ (Costings and Commissioning Analyst at NICE) and JMB (NICE Editor) who will be giving presentations later in the day.

Apologies for absence were received from: Rob Jones (Day 1), Ash Chandra (Day 1), Luke Hounsome (Day 2), Elise Hasler and Katie Perryman Ford. James Catto did not attend the meeting.

##### 2. Declarations of interest

RH declared the following new interests:

- Chief investigator of RAIDER trial (A randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of

transitional cell carcinoma of the bladder). Funded by Cancer Research UK. This interest was categorised as non-personal pecuniary specific, meaning that RH can participate in discussion of all topics as the trial is not funded by the healthcare industry.

- Chief investigator of HYBRID trial (A multicentre randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning in patients with muscle invasive bladder cancer). Funded by Cancer Research UK. This interest was categorised as non-personal pecuniary specific, meaning that RH can participate in discussion of all topics as the trial is not funded by the healthcare industry.
- Will receive reimbursement of travel expenses from Janssen Pharmaceuticals to attend ASCO in June 2014. This interest was categorised as personal pecuniary, non-specific meaning that RH can participate in discussions on all topics as expenses not beyond a reasonable amount.
- Invited to speak on bladder cancer radiotherapy at the East Anglian Bladder meeting in October 2014. No fee will be received. This interest was categorised as personal non-pecuniary, with a chairpersons action that RH can participate in discussions on all topics.
- Spoke on bladder cancer image guided radiotherapy at Royal College of Radiologists meetings in April. No fee received. Has been asked to do the same thing in June 2014. This interest was categorised as personal non-pecuniary, with a chairpersons action that RH can participate in discussions on all topics.
- Has been invited to talk on the RAIDER trial at the Australian Radiotherapy/Cancer meeting in September 2014. No fee received. This interest was categorised as personal non-pecuniary, with a chairpersons action that RH can participate in discussions on all topics.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that necessary action can be taken.

### 3. Discussion

The clinical evidence and final results for the health economic analysis for topic K1 were presented. The GDG agreed draft recommendations and a LETR table.

The GDG discussed the evidence and agreed the recommendations and LETR tables for topics A1 and D1.

The GDG received presentations on the costing and editorial support provided for the guideline.

The GDG reviewed the draft recommendations, LETR tables and editorial comments for topics D2, D3, D4, A3, L1, L2, F2 & F3.

The GDG agreed the definitions of risk to be used in the guideline.

### 4. Close of meeting

JV thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Monday 16<sup>th</sup> June and Tuesday 17<sup>th</sup> June 2014, starting at 10.30am** in the **Board Room, NCC-C, Cardiff**, and closed the meeting.